Sign in Subscribe
Health care industry

Bionomics and LSUHSC-S Collaborate on Groundbreaking Cancer Research

Strategic Insights

— 1 min read

The Louisiana State University Health Sciences Center in Shreveport (LSUHSC-S) and Bionomics Limited have announced a collaborative study to explore the therapeutic potential of a Bionomics proprietary gene (BNO69) in treating cancer. This partnership brings together LSUHSC-S's expertise in gene therapy delivery technology with Bionomics' gene discovery platform, aiming to develop new cancer treatments.

The collaborative study will utilize Dr. J. Michael Mathis's gene delivery technology to deliver gene expression silencing molecules to solid tumors, which may disrupt blood vessel formation and halt tumor growth. Bionomics will retain commercialization rights over any new cancer treatments developed from this collaboration.

Key Takeaways:

  • LSUHSC-S and Bionomics Limited have formed a collaborative agreement to study the therapeutic potential of Bionomics' proprietary gene (BNO69) in treating cancer.
  • The partnership combines LSUHSC-S's gene therapy delivery technology with Bionomics' gene discovery platform to develop new cancer treatments.
  • Dr. J. Michael Mathis's gene delivery technology will be used to deliver gene expression silencing molecules to solid tumors, disrupting blood vessel formation and potentially halting tumor growth.
  • The collaboration aims to leverage Bionomics' Angene platform, which has identified over 600 genes that could be used in the development of new treatments for cancer and other diseases.
  • This partnership builds upon the expertise of both parties, with LSUHSC-S's Gene Therapy Center and Bionomics' Angene platform working together to advance the treatment of cancer.
  • The collaboration will involve research involving cellular and animal models of cancer to generate new data and intellectual property based on proprietary angiogenesis genes discovered by Bionomics.
  • Dr. Gabriel Kremmidiotis, Director of Cancer Research at Bionomics, has highlighted the potential for antiangiogenic therapies in treating various types of cancer, including breast, head, and neck, and prostate cancers.
  • Bionomics has strong expertise in angiogenesis, as seen in the FDA approval of anti-angiogenesis therapeutics for the treatment of colorectal cancer, earlier this year.

Statistics:

  • Over 600 genes have been identified in Bionomics' Angene platform that could be used in the development of new treatments for cancer and other diseases.
  • The global pharmaceuticals market for diseases that may be treated by angiogenesis-based therapies encompasses an estimated 20% of the US$322 billion market.
  • The FDA has approved anti-angiogenesis therapeutics for the treatment of colorectal cancer earlier this year.

Sources:

  • Bionomics Limited
  • Louisiana State University Health Sciences Center in Shreveport
  • The Louisiana Gene Therapy Research Consortium
  • Bionomics (ASX:BNO, BNOOA, US OTC:BMICY)
  • LSUHSC-SHREVEPORT

Read more